查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600517

基底細胞癌治療市場：按類型、給藥途徑、臨床變異和最終用戶分類 - 全球預測 2025-2030

Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

基底細胞癌治療市場2023年估值為64.7億美元，預計到2024年將達到69.4億美元，複合年成長率為7.67%，到2030年將達到108.7億美元。

基底細胞癌（BCC）是最常見的皮膚癌類型，主要影響表皮的基底細胞。 BCC的治療治療方法多種多樣，包括手術切除、局部藥物治療、放射線治療、動態、光動力治療以及刺猬蛋白通路抑制劑等標靶藥物藥物治療方法。這些治療的需求主要是由於紫外線 (UV) 暴露的增加和人口老化導致基底細胞癌的發生率不斷增加。這些治療方法的應用對於皮膚科門診和醫院都至關重要，最終用戶包括醫療保健提供者、患者、保險公司等。市場成長的推動因素包括微創治療方法的進步、公眾對皮膚癌認知的提高以及政府衛生舉措推動的對早期檢測的重視。此外，遠端醫療平台的激增正在增加諮詢的可近性並推動市場擴張。然而，潛在的限制包括先進治療的高成本、與選擇性治療相關的副作用以及來自非專利替代品的競爭壓力。需要創新的領域包括研究減少副作用和提高療效的新治療配方。人工智慧和機器學習的增強對於皮膚癌的早期檢測和個人化治療建議也有希望。還有機會擴展數位健康監測工具的整合，以促進對患者結果的持續追蹤。可能阻礙市場成長的挑戰包括監管障礙、新興市場的報銷問題以及熟練的皮膚腫瘤學專家的短缺。公司應專注於與研究機構的策略夥伴關係，並投資於全面的宣傳宣傳活動，以加強其創新產品平臺。擴大治療組合和市場覆蓋範圍的併購可能是有益的，特別是在服務不足的地區。了解快速變化的市場動態需要不斷適應和投資尖端研究。

主要市場統計
基準年[2023] 64.7億美元
預測年份 [2024] 69.4億美元
預測年份 [2030] 108.7億美元
複合年成長率（%） 7.67%

市場動態：快速發展的基底細胞癌治療市場的關鍵市場洞察

供需的動態交互作用正在改變基底細胞癌治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球基底細胞癌的盛行率
    • 全球對皮膚癌早期診斷和治療的認知不斷增強
  • 市場限制因素
    • 基底細胞癌治療高成本
  • 市場機會
    • BCC 治療的進展和改進
    • 遠端醫療和遠距皮膚病學的新趨勢
  • 市場挑戰
    • 對嚴格法規核准的擔憂

波特五力：開拓基底細胞癌治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基底細胞癌治療市場的外部影響

外部宏觀環境因素在塑造基底細胞癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解基底細胞癌治療市場的競爭狀況

基底細胞癌治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣基底細胞癌治療市場供應商績效評估

FPNV定位矩陣是評估基底細胞癌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪基底細胞癌治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對基底細胞癌治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球基底細胞癌的盛行率
      • 全球對皮膚癌早期診斷和治療的認知不斷提高
    • 抑制因素
      • 基底細胞癌治療費用高
    • 機會
      • BCC 治療的進展和改進
      • 遠端醫療和遠距皮膚病學的新興趨勢
    • 任務
      • 對嚴格監管核准的擔憂
  • 市場區隔分析
    • 治療類型：高效藥物治療和手術介入以徹底擴大BCC
    • 給藥途徑：腸胃外給藥起效迅速，適合治療嚴重的BCC病例。
    • 臨床變化：我們專注於改進和提供針對 BCC 的先進治療方法，以控制硬化性和表面擴散性 BCC 的侵襲性。
    • 最終使用者：政府對醫院和診所設施的擴建和現代化的支持。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章基底細胞癌治療市場：依類型

  • 藥物治療
    • 免疫療法
    • 口腔醫學
    • 標靶治療
    • 外用藥物
  • 放射治療
  • 外科手術

第7章基底細胞癌治療市場：依給藥途徑

  • 口服
  • 胃腸外的

第8章依臨床類型分類的基底細胞癌治療市場

  • 結節性基底細胞癌
  • 色素性基底細胞癌
  • 硬化性基底細胞癌
  • 表淺擴散性基底細胞癌

第9章基底細胞癌治療市場：依最終用戶分類

  • 居家護理
  • 醫院/診所
  • 專業中心

第10章美洲基底細胞癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區基底細胞癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲基底細胞癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Elekta 推出 Evo，一款革命性的自我調整CT 直線加速器，可增強癌症治療
    • Medicus Pharma Co., Ltd.透過策略性收購和加強監管策略來推進基底細胞癌治療
    • Medicus Pharma Ltd. 在非侵入性基底細胞癌治療方面的創新進展、監管發展和臨床研究更新。
    • FDA核准的創新設備增強了基層醫療機構中皮膚癌的早期檢測
    • 基底細胞癌非手術治療方法 VP-315 2 期試驗的最終入組和劑量
    • Medison Pharma 與 Regeneron 之間的策略聯盟增強了 Ribtayo 在癌症治療中的全球使用
    • 艾伯維 (AbbVie) 與 Umoja Biopharma 建立策略聯盟，透過創新嵌合體抗原受體 (CAR) T 細胞療法推進腫瘤治療
    • Medicus Pharma 進行的一項創新性 2 期臨床試驗針對基底細胞癌的非侵入性治療。
    • 百時美施貴寶透過策略性收購加強腫瘤產品組合
    • 歐盟核准Ribtayo 治療進行性肺癌擴大了治療可能性
  • 戰略分析和建議
    • 博士健康公司有限公司
    • 百時美施貴寶公司
    • 再生元製藥公司
    • F.霍夫曼拉羅氏股份公司
    • 太陽製藥工業有限公司

公司名單

  • AbbVie Inc.
  • Almirall, LLC
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma SA
  • Glenmark Pharmaceuticals Limited
  • LEO Pharma A/S
  • Medicus Pharma Ltd.
  • Medivir AB
  • OncoBeta GmbH
  • Perrigo Company PLC
  • Redx Pharma PLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • SkinCure Oncology
  • Sol-Gel Technologies Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-5C6F41F5B0CA

The Basal Cell Carcinoma Treatment Market was valued at USD 6.47 billion in 2023, expected to reach USD 6.94 billion in 2024, and is projected to grow at a CAGR of 7.67%, to USD 10.87 billion by 2030.

Basal Cell Carcinoma (BCC) is the most prevalent form of skin cancer, primarily affecting the epidermal basal cells. The scope of BCC treatment encompasses a variety of therapies, including surgical excision, topical medications, radiation therapy, cryotherapy, photodynamic therapy, and targeted pharmacological approaches, such as hedgehog pathway inhibitors. The necessity for these treatments stems from the rising incidence of BCC, largely due to increased ultraviolet (UV) exposure and aging populations. Applications of these therapies are crucial in both outpatient dermatology clinics and hospitals, with end-users including healthcare providers, patients, and insurance companies. Market growth is being propelled by advancements in less invasive treatments, increasing public awareness about skin cancer, and greater emphasis on early detection, fueled by governmental health initiatives. Additionally, the surge in telemedicine platforms has enhanced accessibility to consultations, fostering market expansion. However, potential constraints include the high cost of advanced treatments, side effects associated with select therapies, and the competitive pressure from generic alternatives. Areas ripe for innovation include research into novel treatment formulations that offer reduced side effects and improved efficacy. Enhancements in AI and machine learning for early skin cancer detection and personalized treatment recommendations are also promising. An expanding opportunity lies in the integration of digital health monitoring tools to facilitate continuous patient outcomes tracking. Challenges that may impede market growth encompass regulatory hurdles, reimbursement issues in emerging markets, and the limited availability of highly skilled dermatologic oncology professionals. Companies should focus on strategic collaborations with research institutions to bolster innovative product pipelines and invest in comprehensive awareness campaigns. Engaging in mergers and acquisitions to expand treatment portfolios and market reach, particularly in underserved regions, could be beneficial. Understanding the dynamics of this rapidly evolving market necessitates continual adaptation and investment in cutting-edge research.

KEY MARKET STATISTICS
Base Year [2023] USD 6.47 billion
Estimated Year [2024] USD 6.94 billion
Forecast Year [2030] USD 10.87 billion
CAGR (%) 7.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Basal Cell Carcinoma Treatment Market

The Basal Cell Carcinoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of basal cell carcinoma worldwide
    • Growing awareness regarding early diagnosis and treatment of skin cancer globally
  • Market Restraints
    • High cost of basal cell carcinoma treatment
  • Market Opportunities
    • Advancements and improvements in BCC treatment
    • Emerging trend of telemedicine and teledermatology
  • Market Challenges
    • Concerns associated with stringent regulatory approval

Porter's Five Forces: A Strategic Tool for Navigating the Basal Cell Carcinoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Basal Cell Carcinoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Basal Cell Carcinoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Basal Cell Carcinoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Basal Cell Carcinoma Treatment Market

A detailed market share analysis in the Basal Cell Carcinoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Basal Cell Carcinoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Basal Cell Carcinoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Basal Cell Carcinoma Treatment Market

A strategic analysis of the Basal Cell Carcinoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Basal Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, LLC, Amgen Inc., Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., Glenmark Pharmaceuticals Limited, LEO Pharma A/S, Medicus Pharma Ltd., Medivir AB, OncoBeta GmbH, Perrigo Company PLC, Redx Pharma PLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., SkinCure Oncology, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Basal Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Drug Therapy, Radiation Therapy, and Surgery. The Drug Therapy is further studied across Immunotherapy, Oral Medications, Targeted Therapy, and Topical Medications.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Clinical Variant, market is studied across Nodular Basal Cell Carcinoma, Pigmented Basal Cell Carcinoma, Sclerosing Basal Cell Carcinoma, and Superficial Spreading Basal Cell Carcinoma.
  • Based on End-Users, market is studied across Homecare, Hospitals & Clinics, and Specialty Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Illinois, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of basal cell carcinoma worldwide
      • 5.1.1.2. Growing awareness regarding early diagnosis and treatment of skin cancer globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of basal cell carcinoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and improvements in BCC treatment
      • 5.1.3.2. Emerging trend of telemedicine and teledermatology
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with stringent regulatory approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
    • 5.2.2. Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
    • 5.2.3. Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
    • 5.2.4. End-Users: Government support for expanding and modernizing hospital and clinic facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Basal Cell Carcinoma Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Drug Therapy
    • 6.2.1. Immunotherapy
    • 6.2.2. Oral Medications
    • 6.2.3. Targeted Therapy
    • 6.2.4. Topical Medications
  • 6.3. Radiation Therapy
  • 6.4. Surgery

7. Basal Cell Carcinoma Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Basal Cell Carcinoma Treatment Market, by Clinical Variant

  • 8.1. Introduction
  • 8.2. Nodular Basal Cell Carcinoma
  • 8.3. Pigmented Basal Cell Carcinoma
  • 8.4. Sclerosing Basal Cell Carcinoma
  • 8.5. Superficial Spreading Basal Cell Carcinoma

9. Basal Cell Carcinoma Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals & Clinics
  • 9.4. Specialty Centres

10. Americas Basal Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Basal Cell Carcinoma Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Basal Cell Carcinoma Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment
    • 13.3.2. Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies
    • 13.3.3. Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies
    • 13.3.4. Groundbreaking FDA-Cleared Device Enhances Early Detection of Skin Cancer in Primary Care Settings
    • 13.3.5. Final Enrollment and Dosing in Phase 2 Trial of a Non-Surgical Treatment VP-315 for Basal Cell Carcinoma
    • 13.3.6. Strategic Collaboration Between Medison Pharma and Regeneron to Enhance Global Access to Libtayo for Cancer Treatment
    • 13.3.7. Strategic Collaboration between AbbVie and Umoja Biopharma to Advance Oncology Treatment with Innovative Chimeric Antigen Receptor (CAR) T-cell Therapies
    • 13.3.8. Innovative Phase 2 Clinical Study by Medicus Pharma Targets Non-Invasive Treatment for Basal Cell Carcinoma
    • 13.3.9. Bristol Myers Squibb Enhances Oncology Portfolio Through Strategic Acquisitions
    • 13.3.10. EU Approval of Libtayo for Advanced Lung Cancer Broadens Treatment Horizons
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Bausch Health Companies Inc.
    • 13.4.2. Bristol-Myers Squibb Company
    • 13.4.3. Regeneron Pharmaceuticals, Inc.
    • 13.4.4. F. Hoffmann-La Roche AG
    • 13.4.5. Sun Pharmaceutical Industries Ltd.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Almirall, LLC
  • 3. Amgen Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Biofrontera AG
  • 6. Bristol-Myers Squibb Company
  • 7. Elekta AB
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche AG
  • 10. Galderma S.A.
  • 11. Glenmark Pharmaceuticals Limited
  • 12. LEO Pharma A/S
  • 13. Medicus Pharma Ltd.
  • 14. Medivir AB
  • 15. OncoBeta GmbH
  • 16. Perrigo Company PLC
  • 17. Redx Pharma PLC
  • 18. Regeneron Pharmaceuticals, Inc.
  • 19. Sanofi S.A.
  • 20. SkinCure Oncology
  • 21. Sol-Gel Technologies Ltd.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BASAL CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BASAL CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BASAL CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 237. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023